WuXi Biologics Sets ESG Benchmark in Biopharma Manufacturing
HONG KONG | December 23, 2025 — WuXi Biologics has been recognized at the Hong Kong ESG Reporting Awards...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HONG KONG | December 23, 2025 — WuXi Biologics has been recognized at the Hong Kong ESG Reporting Awards...
REYKJAVÍK, Iceland; LONDON, United Kingdom — December 22, 2025 — Alvotech has announced the European launch of the world’s...
